Intelligence Profile
Research Papers
Key Research Papers and Clinical Trials
Current research on MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) spans several therapeutic areas, with studies examining its role in metabolism, inflammation, and tissue protection.
Metabolic and Cardiovascular Research
A Phase 2 clinical trial (NCT07505745) is currently recruiting participants to evaluate MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight/obesity, representing the most advanced therapeutic investigation to date.
Recent preclinical studies have demonstrated MOTS-c's cardioprotective effects. One study found that MOTS-c preserves mitochondrial function and genetic integrity to reduce cardiac ischemia-reperfusion injury. Another investigation showed that both MOTS-c and humanin can reduce atrial fibrillation by suppressing tissue fibrosis and mitochondrial dysfunction.
Anti-Inflammatory Properties
Multiple studies have explored MOTS-c's anti-inflammatory effects across different conditions. Research in diabetic rats demonstrated that MOTS-c suppresses both systemic and cardiac inflammasome activation. A review article discussed MOTS-c's potential as a treatment for inflammatory lung diseases, highlighting its secreted mitochondrial microprotein properties.
Clinical Associations and Biomarker Studies
Observational research has identified reduced circulating MOTS-c levels in patients with Hashimoto's thyroiditis, suggesting the peptide may serve as a biomarker reflecting autoimmune and metabolic dysfunction. Another study examined circulating MOTS-c levels in individuals with cerebral palsy, both at rest and following endurance exercise.
Tissue Protection and Regeneration
Research on MOTS-c's effects on tissue health shows mixed results. While one study found that MOTS-c partially protects against skeletal muscle deterioration in a cancer cachexia model (C26), another investigation reported that although MOTS-c activates metabolic signaling in human mesenchymal stromal cells, it may actually impair their reparative function.
Current Limitations
Several ongoing clinical trials are examining MOTS-c in various contexts, including cardiovascular disease in diabetics (NCT04027712) and anesthesia effects during renal transplantation (NCT07678073), though their status and preliminary results are not yet available.
The research base for MOTS-c remains primarily preclinical, with most human studies focusing on biomarker associations rather than therapeutic interventions. The single Phase 2 trial for metabolic applications represents an important step toward clinical validation.
Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers before considering any experimental treatments.